Navrogen Granted Patents on Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate
CHEYNEY, PA, UNITED STATES, October 30, 2025 /EINPresswire.com/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for cancer, announced today that it has been granted patents by the European Patent …